Len Liptak - ProSomnus, Common CEO CoFounder
Insider
Len Liptak is CEO CoFounder of ProSomnus, Common Stock
| Phone | 844 537 5337 |
| Web | https://www.prosomnus.com |
Len Liptak Latest Insider Activity
Tracking and analyzing the buying and selling activities of Len Liptak against ProSomnus, Common stock is an integral part of due diligence when investing in ProSomnus, Common. Len Liptak insider activity provides valuable insight into whether ProSomnus, Common is net buyers or sellers over its current business cycle. Note, ProSomnus, Common insiders must abide by specific rules, including filing SEC forms every time they buy or sell ProSomnus, Common'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Len Liptak over a year ago Acquisition by Len Liptak of 1322756 shares of ProSomnus Common subject to Rule 16b-3 |
ProSomnus, Common Management Efficiency
The company has Return on Asset of (0.4015) % which means that on every $100 spent on assets, it lost $0.4015. This is way below average. ProSomnus, Common's management efficiency ratios could be used to measure how well ProSomnus, Common manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Andrew Green | Artivion | 52 | |
| Ehab Esmail | Orthofix Medical | 53 | |
| Scott Capps | Artivion | 53 | |
| Andre Marquette | Neuropace | N/A | |
| Margaret Carthy | Integer Holdings Corp | 60 | |
| Daniel Bevevino | Artivion | 61 | |
| John Glenn | Iradimed Co | 63 | |
| Geoffrey Rose | Pulmonx Corp | 51 | |
| Sri Radhakrishnan | Pulmonx Corp | N/A | |
| Joshua Wells | Artivion | N/A | |
| Chi Nguyen | Neuropace | 47 | |
| David Colleran | Anika Therapeutics | 52 | |
| Mark Saxton | Neuropace | 59 | |
| John McKune | Pulmonx Corp | 49 | |
| Salvador Dada | Establishment Labs Holdings | 42 | |
| Christopher Holland | Electromed | 55 | |
| Rochelle Maney | Artivion | 45 | |
| Rajbir Denhoy | Establishment Labs Holdings | 54 | |
| Michael Favet | Neuropace | 54 | |
| John Davis | Artivion | 60 | |
| Barbara Schwarzentraub | CONMED | 53 | |
Management Performance
| Return On Asset | -0.4 |
ProSomnus, Common Stock Leadership Team
Elected by the shareholders, the ProSomnus, Common's board of directors comprises two types of representatives: ProSomnus, Common inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ProSomnus,. The board's role is to monitor ProSomnus, Common's management team and ensure that shareholders' interests are well served. ProSomnus, Common's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ProSomnus, Common's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sung Kim, CoFounder CTO | ||
| Mindy Hungerman, Chief Officer | ||
| Jerry Vogel, VP Sales | ||
| Heather Whalen, VP Communications | ||
| Len Liptak, CEO CoFounder | ||
| Shouresh DDS, Global Chair | ||
| Leonard Liptak, CEO CoFounder | ||
| Laing Rikkers, Cofounder Chairman | ||
| Brian Dow, Chief Officer | ||
| John MD, Chief Scientist |
ProSomnus, Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ProSomnus, Common a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.4 | |||
| Profit Margin | (0.87) % | |||
| Operating Margin | (0.64) % | |||
| Current Valuation | 16.13 M | |||
| Shares Outstanding | 17.39 M | |||
| Shares Owned By Insiders | 20.63 % | |||
| Shares Owned By Institutions | 57.01 % | |||
| Number Of Shares Shorted | 73.91 K | |||
| Price To Sales | 0.30 X | |||
| Revenue | 27.65 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Other Consideration for investing in ProSomnus, Stock
If you are still planning to invest in ProSomnus, Common Stock check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ProSomnus, Common's history and understand the potential risks before investing.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |